Viking Therapeutics (VKTX) has never sold a pill. It has no revenue line, no commercial infrastructure, and its lead drug — the oral GLP-1/GIP dual agonist VK2735 — isn't entering Phase 3 until the third quarter of 2026, after Viking wrapped an end-of-Phase-2 meeting with the FDA. Every dollar of Viking's valuation is a bet on two things happening on Washington's clock rather than Viking's: how fast FDA moves a review, and whether federal payers actually pay for what gets approved.
That second variable just became real. On July 1, 2026, CMS activated the Medicare GLP-1 Bridge, a demonstration that pays for Wegovy and Zepbound for eligible beneficiaries with a $50 copay outside the normal Part D benefit structure — the first crack in Medicare's longstanding statutory exclusion of anti-obesity drugs. CMS has paired it with the BALANCE Model, aimed at getting Part D plans and Medicaid programs to cover GLP-1s for weight management long-term. This is the mechanism that turns "biotech science" into "policy optionality": a favorable, durable coverage regime multiplies the addressable market for every obesity drug in the class — including one, like Viking's, that isn't even approved yet.